

AMENDMENTS

In the Claims:

1. (Currently Amended) A method of treating a host suffering from a urologic disorder, said method comprising:
intravesically administering into the lumen of the bladder of said host an effective amount of a neurotoxin to treat said host for said urologic disorder; wherein said administering comprises employing a delivery device with an inflateable component and said method comprises inflating said inflateable component prior to, during, or after administration of said neurotoxin.
2. (Original) The method according to Claim 1, wherein said host is a human.
3. (Original) The method according to Claim 1, wherein said urologic disorder is a bladder disorder.
4. (Original) The method according to Claim 3, wherein said bladder disorder is urinary incontinence.
5. (Original) The method according to Claim 1, wherein said neurotoxin is a botulinum toxin.
6. (Original) The method according to Claim 1, wherein said method further comprises intravesically administering at least one neurotoxin permeability modulating agent to said host.

7. (Original) The method according to Claim 6, wherein said at least one neurotoxin permeability modulating agent is administered to said host prior to said neurotoxin.
8. (Original) The method according to Claim 6, wherein said at least one neurotoxin permeability modulating agent is administered to said host after said neurotoxin.
9. (Original) The method according to Claim 6, wherein said at least one neurotoxin permeability modulating agent is administered to said host simultaneously with said neurotoxin.
10. (Original) The method according to Claim 1, wherein said method further comprises administering to said host at least one additional agent to treat said urologic condition.
11. (Currently Amended) The method according to Claim 1, wherein said ~~neurotoxin is administered to said host with~~ **delivery device is** a catheter.
12. (Canceled)
13. (Original) The method according to Claim 1, wherein said neurotoxin is administered in a reservoir.
- Claims 14-15 (Canceled)
16. (Original) The method according to Claim 1, wherein said administering includes electromotive drug administration.
- Claims 17-23 (Canceled)

Please add the following new claims:

24. (New) A method of treating a host suffering from a urologic disorder, said method comprising:

intravesically administering into the lumen of the bladder of said host an effective amount of a neurotoxin to treat said host for said urologic disorder; wherein said method further comprises at least one of:

(a) intravesically administering said neurotoxin with delivery device that includes an expandable element that occupies a space within the bladder during said administering;

(b) intravesically administering said neurotoxin with a delivery device that includes an element that fixes said delivery device within the bladder; and

(c) intravesically administering said neurotoxin in manner sufficient to enhance neurotoxin contact with the inside of the bladder.

25. (New) The method according to Claim 24, wherein said method comprises intravesically administering said neurotoxin with delivery device that includes an expandable element that occupies a space within the bladder during said administering.

26. (New) The method according to Claim 24, wherein said method comprises intravesically administering said neurotoxin with a delivery device that includes an element that fixes said delivery device within the bladder

27. (New) The method according to Claim 24, wherein said method comprises intravesically administering said neurotoxin in manner sufficient to enhance neurotoxin contact with the inside of the bladder.

28. (New) A method of treating a host suffering from a urologic disorder, said method comprising:

emptying the bladder of said host;

intravesically administering at least one neurotoxin permeability modulating agent to said host; and

intravesically administering to the lumen of the bladder of said host an effective amount of a neurotoxin to treat said host for said urologic disorder.

29. (New) The method according to Claim 28, wherein said host is a human.

30. (New) The method according to Claim 28, wherein said urologic disorder is a bladder disorder.

31. (New) The method according to Claim 30, wherein said bladder disorder is urinary incontinence.

32. (New) The method according to Claim 28, wherein said neurotoxin is a botulinum toxin.